{"id":"https://openalex.org/W2906009666","doi":"https://doi.org/10.1136/jnnp-2018-ehdn.262","title":"J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington\u2019s disease (hd)","display_name":"J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington\u2019s disease (hd)","publication_year":2018,"publication_date":"2018-09-01","ids":{"openalex":"https://openalex.org/W2906009666","doi":"https://doi.org/10.1136/jnnp-2018-ehdn.262","mag":"2906009666"},"language":"en","primary_location":{"id":"doi:10.1136/jnnp-2018-ehdn.262","doi":"https://doi.org/10.1136/jnnp-2018-ehdn.262","is_oa":false,"landing_page_url":"https://doi.org/10.1136/jnnp-2018-ehdn.262","pdf_url":null,"source":{"id":"https://openalex.org/S134773490","display_name":"Journal of Neurology Neurosurgery & Psychiatry","issn_l":"0022-3050","issn":["0022-3050","1468-330X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008618034","display_name":"Scott Schobel","orcid":"https://orcid.org/0000-0001-6182-1943","observed_orcids":["https://orcid.org/0000-0001-6182-1943"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Scott Schobel","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Giuseppe Palermo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Giuseppe Palermo","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012595109","display_name":"Dylan Trundell","orcid":"https://orcid.org/0000-0003-3542-8181","observed_orcids":["https://orcid.org/0000-0003-3542-8181"]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dylan Trundell","raw_affiliation_strings":["Roche Products Ltd, Welwyn Garden City, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Products Ltd, Welwyn Garden City, UK","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Thomas Kremer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Thomas Kremer","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015121920","display_name":"Patricia Sanwald Ducray","orcid":"https://orcid.org/0000-0002-2904-5857","observed_orcids":["https://orcid.org/0000-0002-2904-5857"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Patricia Sanwald-Ducray","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054594438","display_name":"Anne V. Smith","orcid":"https://orcid.org/0000-0001-8190-3006","observed_orcids":["https://orcid.org/0000-0001-8190-3006"]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Smith","raw_affiliation_strings":["Ionis Pharmaceuticals Inc, Carlsbad, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ionis Pharmaceuticals Inc, Carlsbad, CA, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005910368","display_name":"Lauren M. Boak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Lauren Boak","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068308578","display_name":"Rachelle Smith Doody","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"Rachelle Doody","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland","Genentech Inc., South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Genentech Inc., South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A98.1","last_page":"A98"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10949","display_name":"Genetic Neurodegenerative Diseases","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10949","display_name":"Genetic Neurodegenerative Diseases","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10945","display_name":"Lysosomal Storage Disorders Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10855","display_name":"Amyotrophic Lateral Sclerosis Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":0.9430000185966492},{"id":"https://openalex.org/keywords/huntington-s-disease","display_name":"Huntington's disease","score":0.8610000014305115},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.6209999918937683},{"id":"https://openalex.org/keywords/clinical-trial-endpoints","display_name":"clinical trial endpoints","score":0.5950000286102295},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7039999961853027},{"id":"https://openalex.org/keywords/natural-history-disease","display_name":"natural history (disease)","score":0.5839999914169312},{"id":"https://openalex.org/keywords/digital-monitoring","display_name":"digital monitoring","score":0.5730000138282776}],"concepts":[{"id":"https://openalex.org/C2781427258","wikidata":"https://www.wikidata.org/wiki/Q2620886","display_name":"Huntingtin","level":4,"score":0.7595169544219971},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6362180113792419},{"id":"https://openalex.org/C2780647506","wikidata":"https://www.wikidata.org/wiki/Q190564","display_name":"Huntington's disease","level":3,"score":0.5919743180274963},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5614726543426514},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.49428749084472656},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.44233042001724243},{"id":"https://openalex.org/C2910011555","wikidata":"https://www.wikidata.org/wiki/Q2620886","display_name":"Huntingtin Protein","level":5,"score":0.434679239988327},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4274172782897949},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42605316638946533},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3656858205795288},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2837586998939514},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jnnp-2018-ehdn.262","doi":"https://doi.org/10.1136/jnnp-2018-ehdn.262","is_oa":false,"landing_page_url":"https://doi.org/10.1136/jnnp-2018-ehdn.262","pdf_url":null,"source":{"id":"https://openalex.org/S134773490","display_name":"Journal of Neurology Neurosurgery & Psychiatry","issn_l":"0022-3050","issn":["0022-3050","1468-330X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2892219070","https://openalex.org/W2802276893","https://openalex.org/W3012750149","https://openalex.org/W2526348597","https://openalex.org/W7019807759","https://openalex.org/W2944399192","https://openalex.org/W4232877437","https://openalex.org/W3176618606","https://openalex.org/W2891263300","https://openalex.org/W3130284171"],"abstract_inverted_index":{"Background":[0],"RG6042":[1,29,132,219],"(formerly":[2],"IONIS-HTTRx)":[3],"is":[4,63],"a":[5,23,47,118,176],"non-allele-specific,":[6],"huntingtin":[7,216],"mRNA-targeting":[8],"antisense":[9],"oligonucleotide":[10],"which":[11],"reversibly":[12],"suppresses":[13],"production":[14],"of":[15,18,26,59,68,70,81,131,148,159,179,214,230,234],"all":[16],"forms":[17],"Huntingtin":[19],"protein":[20],"(HTT).":[21],"In":[22],"first-in-human":[24],"test":[25],"this":[27],"approach,":[28],"safely":[30],"lowered":[31],"the":[32,56,64,91,100,140,160,184,209,215,231],"pathogenic":[33],"mutant":[34],"HTT":[35],"(mHTT)":[36],"in":[37,55,133,175,236],"early":[38,134],"Huntington\u2019s":[39],"disease":[40,237],"(HD)":[41],"patients,":[42,137],"prompting":[43],"Roche":[44,200],"to":[45,52,94,103,125],"begin":[46],"Global":[48,114,201],"Development":[49,115,202],"Program.":[50],"Questions":[51],"be":[53,74,83,104,196],"answered":[54],"next":[57],"phase":[58],"development":[60],"include:":[61],"what":[62,89],"ultimate":[65],"sustained":[66],"magnitude":[67],"lowering":[69,80,217],"mHTT":[71,82,235],"that":[72],"can":[73],"achieved":[75],"over":[76,109],"long-term":[77],"dosing;":[78],"will":[79,99,195,204],"associated":[84],"with":[85,222],"clinical":[86,127,146,210],"benefit":[87,211],"and":[88,98,106,129,138,166,191,212],"are":[90],"best":[92],"ways":[93],"measure":[95],"such":[96],"benefit;":[97],"approach":[101],"prove":[102],"safe":[105],"well":[107,225],"tolerated":[108],"longer-term":[110],"dosing?":[111],"Method/results":[112],"This":[113],"Program":[116,203],"includes":[117,153],"single,":[119],"pivotal,":[120],"24-month":[121],"efficacy":[122,128],"study":[123,158,164,188],"designed":[124],"demonstrate":[126],"safety":[130,213],"manifest":[135],"HD":[136],"examine":[139],"effects":[141],"on":[142,208],"slowing":[143],"or":[144],"stopping":[145],"progression":[147],"HD.":[149],"The":[150,181,199],"program":[151],"also":[152],"an":[154,167],"ongoing,":[155],"open-label":[156],"extension":[157],"completed":[161],"Phase":[162],"I/IIa":[163],"(NCT03342053),":[165],"observational":[168],"natural":[169],"history":[170],"study,":[171],"both":[172],"being":[173],"conducted":[174],"limited":[177],"number":[178],"sites.":[180],"rationale":[182],"for":[183,220],"target":[185],"population,":[186],"pivotal":[187],"design,":[189],"endpoints":[190],"digital":[192],"monitoring":[193],"tools":[194],"discussed.":[197],"Conclusion":[198],"provide":[205],"valuable":[206],"information":[207],"treatment":[218],"patients":[221],"HD,":[223],"as":[224,226],"further":[227],"longitudinal":[228],"evidence":[229],"causal":[232],"role":[233],"progression.":[238]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2019-01-01T00:00:00"}